Man Group’s Enliven Therapeutics ELVN Stock Holding History

Man Group’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,371	Closed	-$274K	–	2311
2025 Q3	$274K	Buy	+13,371	New	+$270K	﹤0.01%	2035

Other funds holding ELVN

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Man Group's ELVN Position: Q4 2025 in Review

Man Group sold out of Enliven Therapeutics (ELVN) in Q4 2025, closing a stake of 13,371 shares — an estimated $274K sold.

Man Group first reported a position in ELVN in Q3 2025 and held it in 1 quarter. The position peaked at $274K in Q3 2025. 125 funds tracked by Wall St. Rank hold ELVN as of Q4 2025.

Man Group reported no remaining Enliven Therapeutics position as of Q4 2025 after selling out during the quarter.
Man Group sold 13,371 Enliven Therapeutics shares in Q4 2025, an estimated $274K.
Man Group first reported a position in Enliven Therapeutics in Q3 2025 and held it in 1 quarter.
Man Group's Enliven Therapeutics position peaked at $274K in Q3 2025.
125 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2025.

Based on Man Group's 13F filing for Q4 2025, filed 17 Feb 2026.